Left Menu
Development News Edition

Lilly antibody drug fails in a COVID-19 study; others go on

US government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalised with COVID-19 because it doesn't seem to be helping them. In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness.

PTI | Marakabei | Updated: 27-10-2020 06:13 IST | Created: 27-10-2020 06:13 IST
Lilly antibody drug fails in a COVID-19 study; others go on

US government officials are putting an early end to a study testing an Eli Lilly antibody drug for people hospitalised with COVID-19 because it doesn't seem to be helping them. Independent monitors had paused enrolment in the study two weeks ago because of a possible safety issue. But on Monday, the National Institute of Allergy and Infectious Diseases, which sponsors the study, said a closer look found no safety problem but a low chance that the drug would prove helpful for hospitalized patients.

It is a setback for one of the most promising treatment approaches for COVID-19. President Donald Trump received a similar experimental antibody drug from Regeneron Pharmaceuticals Inc on an emergency basis when he was sickened with the coronavirus earlier this month. In a statement Lilly notes that the government is continuing a separate study testing the antibody drug in mild to moderately ill patients, to try to prevent hospitalization and severe illness. The company also is continuing its own studies testing the drug, which is being developed with the Canadian company AbCellera.

Antibodies are proteins the body makes when an infection occurs; they attach to a virus and help it be eliminated. The experimental drugs are concentrated versions of one or two specific antibodies that worked best against the coronavirus in lab and animal tests. Lilly and Regeneron have asked the U.S. Food and Drug Administration to grant emergency use authorization for their drugs for COVID-19 while late-stage studies continue. Lilly says its request is based on other results that the drug is beneficial.


TRENDING

OPINION / BLOG / INTERVIEW

Turbulence surrounding tobacco control in Ghana

... ...

Smart healthcare: IoT redefining the way healthcare is delivered

As the world is embracing the new wave of digitalization triggered by the pandemic and the arrival of 5G, the adoption of IoT devices will further boom. With adoption set to soar, IoT security issues and other challenges cant be ignored any...

Refugee compassion and response: Ideas to mitigate disasters now and in their future

Their homeland becomes a forbidden territory for them and more likely than not, their journey to foreign soil is no less traumatizing, not to say deadly. It is crucial to help refugees live a life of dignity and purpose....

Inadequate water infrastructure causes a tidal wave of coronavirus in rural Alaska

... ...

Videos

Latest News

US STOCKS-Wall St rises, Nasdaq hits record high on recovery hopes

Wall Streets main indexes rose and the Nasdaq hit a record high on Friday as optimism around an economic rebound next year outweighed concerns around an expected surge in coronavirus infections following the Thanksgiving holiday. Sentiment ...

STPI launches new incubation centre in Dehradun

State-owned Software Technology Parks of India STPI on Friday said it has launched a new incubation centre in Dehradun spread over a built-up area of 30,000 square feet. Telecom and IT Minister Ravi Shankar Prasad said STPI is the first sta...

FACTBOX-Soccer-Reaction from club managers to the death of Maradona

Following is a selection of quotes from top-flight club managers on Diego Maradona, following his death Napoli manager Gennaro GattusoThe greatest regret I have is probably the fact that I cant tell my children I played against Maradona. Fo...

China questions coronavirus origin to Wuhan ahead of WHO probe

Battling global adversity over the coronavirus and bracing for a WHO inquiry over its origin, China on Friday claimed that just because COVID-19 cases were first reported in Wuhan does not mean the contagion originated from the central Chin...

Give Feedback